He has rich clinical experience in the fields of cardiovascular surgery such as coronary heart disease, heart valve, congenital heart disease, great vessels and heart transplantation. The annual operation volume reached 1 1,000 cases, and accumulated rich experience in coronary artery bypass grafting 1 1,000 cases, heart valve surgery 2000 cases, great vessel surgery 500 cases, complex congenital heart disease 500 cases and heart transplantation 50 cases. He is good at the surgical treatment of various difficult cardiovascular diseases, including the complications of myocardial infarction such as senile high-risk coronary heart disease and ventricular septal perforation, valvular heart disease with huge left ventricle and severe low EF, dislocation of great vessels and other complex congenital heart diseases in children, reoperation, late heart disease complicated with heart failure, etc. It is the first in China to carry out off-pump beating coronary artery bypass grafting, minimally invasive coronary artery bypass grafting with small incision, hybrid technology for coronary heart disease, robot-assisted heart surgery and stem cell transplantation for heart failure after myocardial infarction. There are more than 200 rounds of ward rounds, more than 50 third-level inter-hospital consultations and more than 200 operations every year.

Off-pump beating coronary artery bypass grafting, mini-incision minimally invasive coronary artery bypass grafting, coronary heart disease hybridization, robot-assisted heart surgery and stem cell transplantation are the first in China to treat heart failure after coronary heart disease myocardial infarction. He presided over and participated in the national "863" scientific and technological key projects, the "Tenth Five-Year Plan" national scientific and technological key projects, the National Natural Science Foundation, the major scientific research projects of Shanghai Science and Technology Commission, and multi-center clinical research at home and abroad. The research on stem cell transplantation to improve cardiac insufficiency after myocardial infarction, the clinical application of minimally invasive coronary artery bypass grafting, and the treatment of end-stage heart disease by orthotopic heart transplantation have won awards such as China Medical Award, Shanghai Science and Technology Progress Award, Shanghai Medical Science and Technology Award, Shanghai Clinical Medical Achievement Award and Shanghai Talent Development Fund. There are more than 1 10 papers published at home and abroad, including 3 SCI papers10. Participated in the compilation of 9 monographs on cardiothoracic surgery. 36 graduate students have been trained.